Trials / Unknown
UnknownNCT04582955
Neoadjuvant Treatment of Early Triple-negative Breast Cancer With Chidamide and Chemotherapy
Chidamide Combined With Neoadjuvant Chemotherapy in Early Triple-negative Breast Cancer
- Status
- Unknown
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 20 (estimated)
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital · Academic / Other
- Sex
- Female
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
Objective to evaluate the efficacy and safety of neoadjuvant therapy with Chidamide combined with chemotherapy for stage II - III triple-negative breast cancer，and to compare the efficacy and safety of chemotherapy with Chidamide and chemotherapy alone in the neoadjuvant treatment of stage II - III triple-negative breast cancer
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Chidamide in combination with chemotherapy | Chidamide, orally,20mg at day 0,4,7,11,21,every 3 weeks; in combination with Docetaxel 75mg/m2,intravenous infusion，at day1 every 3 weeks，and Epirubicin 75mg/m2, intravenous infusion，at day1 every 3 weeks |
Timeline
- Start date
- 2020-10-30
- Primary completion
- 2022-12-01
- Completion
- 2022-12-01
- First posted
- 2020-10-12
- Last updated
- 2020-12-07
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04582955. Inclusion in this directory is not an endorsement.